

COMPREhensive assessment of prevalence, risk factors and mechanisms of impaired medical and psychosocial health outcomes among Adolescents and Young Adults with cancer: the prospective observational COMPRAYA cohort study

Published: 04-08-2020

Last updated: 24-05-2024

To examine the prevalence, risk factors and mechanisms of impaired health outcomes (short- and long-term medical and psychosocial effects and late effects) over time among a population-based sample of AYA cancer patients. Primary Objective: - To...

| | |
|------------------------------|---|
| Ethical review | Approved WMO |
| Status | Recruiting |
| Health condition type | Miscellaneous and site unspecified neoplasms benign |
| Study type | Observational non invasive |

Summary

ID

NL-OMON54428

Source

ToetsingOnline

Brief title

COMPRAYA cohort study

Condition

- Miscellaneous and site unspecified neoplasms benign

Synonym

tumor; carcinoma

Research involving

Human

Sponsors and support

Primary sponsor: Antoni van Leeuwenhoek Ziekenhuis

Source(s) of monetary or material Support: NWO,KWF

Intervention

Keyword: cancer, health outcomes, risk factors, young adults

Outcome measures

Primary outcome

The main outcomes are medical (e.g. second tumour; survival; fertility) and psychosocial (e.g. distress) health outcomes. Other study parameters (covariates/moderators/mediators) are characteristics of the individual (e.g. age, sex, cultural background, partner status, educational level, occupation, tumour type, disease stage, body composition, comorbid conditions, coping style), characteristics of the environment (e.g. cancer treatment, lifestyle), and genetic and biological factors (e.g. family history of cancer, stress and inflammation markers (e.g. cortisol, IL-6), microbiome).

Primary Objective:

- To identify individual, environmental, biological and psychological characteristics of AYA cancer patients who are at high risk for impaired medical and psychosocial health outcomes. In other words: To develop a prediction model for impaired medical and psychosocial health outcomes (at baseline, 2-, 5- and 10-year follow-up).

Secondary outcome

Secondary Objective(s):

-To assess the prevalence of impaired (age-specific) medical (e.g. second tumour) and psychosocial (e.g. social isolation) health outcomes at each time point (at baseline, 2-, 5- and 10-year follow-up).

Exploratory Objective(s):

-To analyse the course of medical and psychosocial health outcomes over time (all timepoints needed)

-To analyse mediating mechanisms associated with impaired health outcomes in AYA cancer patients (at baseline, 2-, 5- and 10-year follow-up).

Other Objective(s):

-To form a prospective observational cohort of patients diagnosed with cancer at AYA age, and follow them over time until death.

Study description

Background summary

Childhood cancer survivorship attracts attention globally, because successes in treatment have led to increasing number of survivors who reach adulthood, in which survivorship issues affecting health-related quality of life (HRQoL) become prominent. Most pediatric patients are treated intensively with irradiation and/or chemotherapy which put them at risk for early and/or late adverse medical and psychosocial events. In contrast, much less is known from adolescent and young adult (AYA) cancer patients, diagnosed between 18-39 years, who, with an 80% chance to survive, also have a long life ahead. AYA cancer patients, much more than children, suffer from delay in diagnosis, lack of centralization of care, age-adjusted expertise (*I am treated like my

74-year-old aunt*) and AYA follow-up care. AYAs typically present with a rare tumor: either with a paediatric malignancy (e.g. acute lymphoblastic leukaemia, paediatric brain tumors), a tumor of AYA age (e.g. Hodgkin's disease, germ cell cancer, melanoma, thyroid cancer) or, unexpectedly, with an adult tumor (e.g. gastrointestinal, lung, breast carcinomas). Next to these differences in epidemiology, tumor biology, developmental challenges (e.g. forming relationships, becoming financially independent, having children) and treatment regimens differ between AYAs and children, and therefore findings derived from childhood cancer survivors cannot be extrapolated to AYAs. Furthermore, novel treatments with targeted agents or immunotherapy are more likely to be administered to AYAs compared to children. Finally, a rare group of incurable AYA cancer patients will survive for many years, for whom health outcome and supportive care intervention data are lacking.

(Inter)nationally, cohort studies exist that address many relevant issues, but all from the perspective of tumor histology, rather than an AYA age-specific perspective. These tumor-specific cohorts do not specifically address unique issues such as:

- (1) Age-specific health outcomes like fertility, late toxicity, family functioning, employment;
- (2) Genetic risk factors and AYA tumor genetics;
- (3) Tumor types with an incurable, protracted behaviour at this young age;
- (4) Age-adjusted early interventions

Globally, so far, the identification of AYA patient subgroups that might be more susceptible to poor health outcomes has not been systematically addressed. The role of sociodemographic and treatment-associated risks, external exposures (e.g. lifestyle) and host factors (e.g. genetic, biological, physiological); or combinations of influences for impaired (age-specific) health outcomes, remains largely unknown. Understanding who is at risk and why will support the development of evidence-based AYA prevention, treatment and supportive care programs and guidelines, in co-creation with AYA cancer patients.

Study objective

To examine the prevalence, risk factors and mechanisms of impaired health outcomes (short- and long-term medical and psychosocial effects and late effects) over time among a population-based sample of AYA cancer patients.

Primary Objective:

- To identify individual, environmental, biological and psychological characteristics of AYA cancer patients who are at high risk for impaired medical and psychosocial health outcomes. In other words: To develop a prediction model for impaired medical and psychosocial health outcomes (at baseline, 2-, 5- and 10-year follow-up).

Secondary Objective(s):

-To assess the prevalence of impaired (age-specific) medical (e.g. second tumour) and psychosocial (e.g. social isolation) health outcomes at each time point (at baseline, 2-, 5- and 10-year follow-up).

Exploratory Objective(s):

-To analyse the course of medical and psychosocial health outcomes over time (all timepoints needed)
-To analyse mediating mechanisms associated with impaired health outcomes in AYA cancer patients (at baseline, 2-, 5- and 10-year follow-up).

Other Objective(s):

-To form a prospective observational cohort of patients diagnosed with cancer at AYA age, and follow them over time until death.

Study design

This is a dynamic prospective study consisting of two study arms namely; COMPRAYA 1.0 and COMRAYA 2.0.

Participating AYAs will be followed over several years to assess their health outcomes. We do this by asking these patients at the individual level to complete an annual questionnaire. In addition, in COMPRAYA 1.0, hair, blood and stool samples will also be taken together with the measurement of the vital parameters, at three time points, namely in the first 6 months after diagnosis, 2 and 5 years after diagnosis. Participants in COMPRAYA 2.0 will only be asked to give blood once and to complete the questionnaires up to a maximum of 10 years after diagnosis.

Also, if the patient gives permission, medical data from the electronic patient record, the Dutch cancer registry and other health-related registrations will be collected.

Tumor tissue can also be used.

At participating hospitals, AYAs will be invited to participate in COMPRAYA.

COMPRAYA 1.0:

At the start of the study, the AYA will sign a consent form for:

- (1) Collection of medical data from the electronic patient record, the Dutch cancer registry and other health-related registries (consent linkage);
- (2) Completion of validated questionnaires on (age-specific) health outcomes;
- (3) Use of tumor tissue known to PALGA;
- (4) Blood collection, storage and subsequent central analysis;
- (5) Hair, stool collection, storage and subsequent analysis
- (6) Hospital visit to measure vital parameters (body composition, strength);

COMPRAYA 2.0

Based on selection from the NKR, appropriate participants will receive an

invitation. They can give consent for participation either digitally or on paper. Following this consent, the participant will be contacted for an appointment to draw blood. The questionnaire can further be completed online or on paper.

Study burden and risks

On an individual level, patients who participate are asked to complete questionnaires on an annual basis for at least 10 years. All sample collections will take place at three time points: 0-6 months after diagnosis (baseline), 2 and 5 years; except blood for DNA analyses which will only take place at baseline. The collection of blood, hair and faeces at three occasions is minimally invasive and the risks of blood draws, hair and fecal sampling are negligible. All safety measures and procedures will be performed according to local guidelines. Patients will not experience direct benefit from participation in the COMPRAYA study.

By participating, patients will contribute to a better insight in the prevalence of impaired medical and psychosocial (age-specific) health outcomes in AYA and evidence on factors associated with these health outcomes. This will lead to better and more personalized cancer care and supportive care tools for future AYA cancer patients.

Contacts

Public

Antoni van Leeuwenhoek Ziekenhuis

plesmanlaan 121
Amsterdam 1066CX
NL

Scientific

Antoni van Leeuwenhoek Ziekenhuis

plesmanlaan 121
Amsterdam 1066CX
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

- COMPRAYA 1.0 All AYAs diagnosed with cancer for the first time between 18-39 years of age, 3 months ago after diagnosis up to max 6 months after diagnosis in 1 of the participating centers

Mentally competent; sufficient understanding of the Dutch language.

COMPRAYA 2.0 All AYAs diagnosed with cancer for the first time between 18-39 years of age from 1999 to 2022, treated in one of the participating centers

Mentally competent; sufficient understanding of the Dutch language.

Exclusion criteria

- Mentally incompetent patients based on the opinion of treating physician .

- Inability to understand the Dutch language

- Life expectancy less than 6 months based on the opinion of treating physician

Study design

Design

Study type: Observational non invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Other

Recruitment

NL

| | |
|---------------------------|------------|
| Recruitment status: | Recruiting |
| Start date (anticipated): | 18-06-2021 |
| Enrollment: | 4000 |
| Type: | Actual |

Ethics review

| | |
|--------------------|------------------|
| Approved WMO | |
| Date: | 29-09-2020 |
| Application type: | First submission |
| Review commission: | METC NedMec |
| Approved WMO | |
| Date: | 27-05-2021 |
| Application type: | Amendment |
| Review commission: | METC NedMec |
| Approved WMO | |
| Date: | 09-12-2021 |
| Application type: | Amendment |
| Review commission: | METC NedMec |
| Approved WMO | |
| Date: | 07-06-2022 |
| Application type: | Amendment |
| Review commission: | METC NedMec |
| Approved WMO | |
| Date: | 01-11-2022 |
| Application type: | Amendment |
| Review commission: | METC NedMec |
| Approved WMO | |
| Date: | 07-12-2022 |
| Application type: | Amendment |
| Review commission: | METC NedMec |
| Approved WMO | |
| Date: | 27-03-2023 |
| Application type: | Amendment |
| Review commission: | METC NedMec |
| Approved WMO | |

| | |
|--------------------|-------------|
| Date: | 21-09-2023 |
| Application type: | Amendment |
| Review commission: | METC NedMec |
| Approved WMO | |
| Date: | 21-05-2024 |
| Application type: | Amendment |
| Review commission: | METC NedMec |

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

| Register | ID |
|----------|----------------|
| CCMO | NL73969.031.20 |